Therefore, a growing interest in the therapeutic and biomarker utility of CXCR4 for patient selection in lung cancer is motivated by the strong evidence that implicates it in lung cancer progression and therapy resistance. This evidence concerns the gene CXCR4 and lung carcinoma.